Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens-Reference-Cited by-同舟云学术

Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens

Published:2014-12-18 Issue:1 Volume:20 Page:77-83
ISSN:1354-750X
Container-title:Biomarkers
language:en
Short-container-title:Biomarkers

Author:

Medrano Alfonso Segarra,Escalante Elias Jatem,Cáceres Clara Carnicer,Pamplona Irene Agraz,Allende Maria Teresa Salcedo,Terrades Natalia Ramos,Carmeno Naiara Valtierra,Roldán Elena Ostos,Agudelo Karla Viviana Arredondo,Vasquez Juliana Jaramillo

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Clinical Biochemistry,Biochemistry

Link

http://www.tandfonline.com/doi/pdf/10.3109/1354750X.2014.993708

Reference26 articles.

1. Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy

2. M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous Nephropathy

3. Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy

4. Antiphospholipase A2Receptor Autoantibodies: A Comparison of Three Different Immunoassays for the Diagnosis of Idiopathic Membranous Nephropathy

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels;BMC Nephrology;2023-09-22

2. M-Type Phospholipase A2 Receptor Autoantibody Measured by ELISA has Diagnostic Value in Patients with Idiopathic Membranous Nephropathy;Clinical Laboratory;2023

3. Primary Nephrotic Syndrome;Nephrology Self-Assessment Program;2022-12

4. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study;PeerJ;2022-10-10

5. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis;International Urology and Nephrology;2022-09-25